LifePlan Financial LLC Purchases 2,978 Shares of Johnson & Johnson (NYSE:JNJ)

LifePlan Financial LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 238.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,227 shares of the company’s stock after acquiring an additional 2,978 shares during the period. LifePlan Financial LLC’s holdings in Johnson & Johnson were worth $611,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. IFS Advisors LLC boosted its stake in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares in the last quarter. Highline Wealth Partners LLC bought a new position in Johnson & Johnson in the 3rd quarter worth $31,000. RPg Family Wealth Advisory LLC bought a new position in Johnson & Johnson in the 3rd quarter worth $35,000. Mowery & Schoenfeld Wealth Management LLC raised its holdings in Johnson & Johnson by 58.7% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares in the last quarter. Finally, Activest Wealth Management bought a new position in Johnson & Johnson in the 3rd quarter worth $40,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.9 %

Shares of JNJ opened at $146.58 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock’s 50 day moving average is $148.10 and its two-hundred day moving average is $156.05. The firm has a market cap of $352.91 billion, a P/E ratio of 21.21, a PEG ratio of 2.52 and a beta of 0.51. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22,438,500 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.29 earnings per share. Analysts predict that Johnson & Johnson will post 9.95 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday. Stifel Nicolaus reduced their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday. Citigroup reduced their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday. Finally, Wells Fargo & Company reduced their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday. Nine analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $170.06.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.